If you are lucky enough to have $3,000 to invest in ASX shares in December, then take a look at the three named below.
They have been tipped as buys by analysts this month. Here's what you need to know about them:
GQG Partners Inc (ASX: GQG)
Goldman Sachs thinks that this fund manager's shares have been oversold and are great value now.
Commenting on its buy recommendation, the broker said:
GQG is a global asset manager with an active equity focus. We are Buy rated on GQG because: 1) Net flow trajectory has been very strong 2) Strong performance has resulted in performance fees becoming increasingly more material 3) Medium and long term relative performance strong 4) Attractive valuation vs. peers in context of very strong earnings growth. 5) Impacts from Adani appear manageable.
Goldman has a buy rating and $2.80 price target on the ASX share.
Pilbara Minerals Ltd (ASX: PLS)
Analysts at Bell Potter think that lithium miner Pilbara Minerals could be a good destination for your funds.
This week, the broker upgraded the company's shares on valuation grounds and on the belief that the lithium market is heading into a supply deficit in 2026. It said:
We upgrade our PLS recommendation to Buy (from Hold) on recent share price weakness. […] We calculate that recent supply curtailments from Australian producers (including PLS) have removed around 50kt of Lithium Carbonate Equivalent from the market (around 4% of 2024 supply). On our supply-demand modelling, the cuts result in a smaller market surplus in 2025 and brings forward our estimate of a market deficit to 2026 (previously 2027).
Bell Potter has put a buy rating and $2.70 price target on its shares.
Pro Medicus Limited (ASX: PME)
Goldman Sachs also thinks that this health imaging technology company could be an ASX share to buy now.
Although the broker concedes that Pro Medicus shares are not cheap, it believes they deserve this premium valuation. Especially given its significant long-term growth opportunity. The broker explains:
We remain positive on the PME equity story as one of Australia's best global growth companies. […] PME is not cheap, trading on 114x FY26E EV/EBITDA, but we highlight its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. Additionally, with a focus on the US regulatory outlook, we believe MedTech is increasingly being evaluated as a safe haven within healthcare as it is generally more insulated from impending policy volatility.
Goldman has a buy rating and $278.00 price target on its shares.
